Search PubMed⌕ Search

Biomedical subjects

A C Pande

Publications and source records attributed to A C Pande.

At least 37 records · Page 2Linked to original sources
PubMed1993

Severity of depression and response to fluoxetine.

Pooled data from multiple, double-blind clinical trials comparing fluoxetine with either placebo, a tricyclic antidepressant (TCA) or both in patients with major depression were analyzed to assess the efficacy of these treatments in mild, moderate and severe depression. Fluoxetine-treated patients showed statistically significantly higher rates of response and remission than placebo-treated patients within all three severity subgroups. There were no differences in response or remission rates between fluoxetine and TCAs, regardless of symptom severity. Thus, the efficacy of fluoxetine was superior to placebo and similar to TCAs in mild, moderate and severe major depression.

Adolescent↗
PubMed1993

Adverse events and treatment discontinuations in fluoxetine clinical trials.

A re-analysis of the profile of adverse events observed in controlled clinical trials in summarized. The data confirm that the side-effects of fluoxetine therapy are different from those of the tricyclic antidepressants (TCAs), both in type and frequency. Moreover, the superior tolerability of fluoxetine compared with the TCAs is confirmed by the significantly lower rate of premature discontinuation in the fluoxetine-treated patients than in the TCA-treated patients.

Antidepressive Agents, Tricyclic↗
PubMed1992

EEG sleep in Cushing's disease and Cushing's syndrome: comparison with patients with major depressive disorder.

Because patients with Cushing' syndrome (CS) and Major depressive disorder (MDD) share features of hypercortisolism and the depressive syndrome, we compared electro-encephalographic (EEG) sleep in patients with pituitary-ACTH-dependent Cushing's syndrome (Cushing's disease, CD), patients with ACTH-independent Cushing's syndrome (AICS), patients with major depressive disorder (MDD), and normal subjects. There were substantial similarities in the abnormal polysomnography profiles of patients with CD, AICS, and MDD. All three patient groups demonstrated poorer sleep continuity, shortened rapid eye movement (REM) latency, and increased first REM period density compared with normal subjects. In addition, AICS patients and MDD patients had elevated REM activity and density. These findings are discussed in terms of models of pathophysiology that relate abnormalities in sleep, mood, and hypothalamic-pituitary-adrenal function.

Adenoma↗
PubMed1991

Heterogeneity in the beta-endorphin immunoreactivity response to electroconvulsive therapy.

Electroconvulsive therapy is accompanied by an activation of the hypothalamic-pituitary-adrenal axis, resulting in a release of beta-endorphin from the anterior pituitary corticotrophs of humans. As a group, patients in our study demonstrated similar plasma beta-endorphin immunoreactivity response to their initial and final treatments. However, approximately half of the patients demonstrated greater beta-endorphin immunoreactivity release with their first seizure compared with their last seizure, and half of the patients demonstrated the opposite pattern. This difference was not explained by age, sex, unilateral vs bilateral treatments, sine wave vs brief pulse, or psychotropic or anticholinergic medication. Patients with constant seizure duration during the first and final treatments demonstrated a greater release of beta-endorphin immunoreactivity with the final treatment compared with the first treatment. Individuals with decreasing seizure duration during the course of the electroconvulsive therapy demonstrated a decreased beta-endorphin immunoreactivity response during their final treatment.

Adult↗
PubMed1990

Electroconvulsive therapy in delusional and non-delusional depressive disorder.

Major depressive disorder (MDD) patients (n = 66) treated with electroconvulsive therapy were stratified by the presence (n = 30) or absence (n = 36) of delusional symptoms (by Research Diagnostic Criteria) to compare their response to treatment. At discharge from hospital 83% of the MDD with psychosis group and 58% of the MDD without psychosis group were good responders (P = 0.03). The implications of this are discussed.

Adult↗
PubMed1990

Comorbidity of panic disorder and major depressive disorder: effects on platelet alpha 2 adrenergic receptors.

Adrenergic receptor dysregulation has been described as occurring in both major depressive disorder (MDD) and panic disorder. Measurements of platelet alpha 2 adrenergic receptors in these patients may be confounded by the coexistence or comorbidity of both diagnoses in the same patient. To explore this possibility, we measured platelet alpha 2 adrenergic receptors (3H-clonidine and 3H-yohimbine binding) in 3 groups of patients (MDD only, panic disorder only, and those showing comorbidity of MDD and panic) and normal controls. Patients with comorbidity of MDD and panic disorder had significantly lower agonist binding (3H-clonidine).

Adult↗
PubMed1988

Major depressive disorder and panic disorder. Effects of comorbidity on treatment outcome with antidepressant medications.

Recent studies suggest that major depressive disorder (MDD) and panic disorder (PD) may coexist in a significant number of patients. The relevance of this association may be such that patients with the simultaneous diagnosis are at risk for more severe psychopathology and poorer treatment outcome. To explore this possibility further, we compared treatment outcome of two groups of patients: one with comorbidity of MDD and PD (N = 19) and another with MDD only (N = 22). Patients with comorbidity of MDD and PD scored significantly worse on a number of outcome assessments.

Antidepressive Agents↗
PubMed1986

Midwinter insomnia.

Explore the source record for details and available documents.

Bipolar Disorder↗